GAITHERSBURG, Md. - An FDA panel generally agreed that Ranexa, CV Therapeutics Inc.'s candidate for chronic angina, is approvable if the company is willing to conduct another clinical trial in a broader population that includes patients who are not resistant to traditional drugs. (BioWorld Today)
GAITHERSBURG, Md. - An FDA panel generally agreed that Ranexa, CV Therapeutics Inc.'s candidate for chronic angina, is approvable if the company is willing to conduct another clinical trial in a broader population that includes patients who are not resistant to traditional drugs. (BioWorld Today)
Preliminary results from a pivotal Phase III trial of Alkermes Inc.'s Vivitrex indicate that a once-monthly injection, along with psychosocial therapy, helps men reduce their rate of heavy drinking. However, the drug does not appear to work as well in women. (BioWorld Today)
Preliminary results from a pivotal Phase III trial of Alkermes Inc.'s Vivitrex indicate that a once-monthly injection, along with psychosocial therapy, helps men reduce their rate of heavy drinking. However, the drug does not appear to work as well in women. (BioWorld Today)
